Next-Generation Biomanufacturing Market Size to Reach USD 54.85 billion in 2032

The Next-Generation Biomanufacturing market, valued at USD 25.10 billion in 2024, is expected to register robust revenue CAGR of 10.2%.

Request free copy of this report: https://navistratanalytics.com/request-free-sample/757

03 April, 2025 - Rising demand for advanced biomanufacturing processes is a key factor driving market revenue growth. As fermentation-based biomanufacturing grows increasingly common, the technology has advanced. Scientists have created new and improved microbes that are more efficient and effective by combining synthetic biology with genetic engineering. This has resulted in the development of bioreactors with increased precision in terms of scalability and control, leading in lower energy consumption and a smaller carbon footprint. Biomanufacturing methods may run continuously, which has various advantages over typical batch manufacturing.

In December 2024, Merck, a prominent scientific and technology business, has introduced the first single-use reactor developed exclusively for producing antibody drug conjugates (ADCs). ADCs are a new family of medicinal medicines that can target and selectively kill tumour cells while preserving healthy ones. The Mobius ADC Reactor is specifically designed to suit the special needs for connecting the relevant components. It enables biopharmaceutical companies to develop important treatments more quickly and safely.

However, there are certain hurdles to overcome. One significant challenge is technological and process complexity. Biomanufacturing, like other new technologies, has a variety of challenges before achieving the level of acceptance that other methods now utilized in the sector do. For example, there are still some technical limits to optimizing yield and process scalability. These concerns may be addressed as demand grows and bioreactor manufacturers develop new inventions that make the process more adaptable.

Want to Know What’s Fueling the Next-Generation Biomanufacturing Market Growth? Get Exclusive Report Insights Here: https://navistratanalytics.com/report_store/next-generation-biomanufacturing-market/

Segments market overview and growth Insights

Based on the workflow, next-generation biomanufacturing market is segmented into single-use upstream biomanufacturing workflow, continuous upstream biomanufacturing, and downstream biomanufacturing workflow. Single-use upstream biomanufacturing workflow segment is expected to register the largest market revenue share during the forecast period. The biopharmaceutical industry's progress and adoption of single-use technology has been fuelled by rising demand for biologics, particularly monoclonal antibodies, and vaccines. Single-use technologies enable speedier development and production of these complex compounds, which must meet strict quality and safety standards. They also make it easier to create modular and flexible facilities that can quickly adjust to changing market needs and regulatory regulations. Single-use components are pre-sterilized and discarded after use, reducing the need to clean and sterilize between batches. This lowers the risk of microbiological or chemical contamination, which can jeopardize the quality and safety of biopharmaceutical products.

On September 2023, Getinge introduced a single-use bioreactor for clinical cell and gene therapy. Getinge's innovative AppliFlex ST GMP is a significant step forward in bioprocessing technology, offering researchers with a complete turn-key solution for converting bioprocesses from laboratory research to clinical applications. Getinge's system includes consumables, auxiliaries, verification, and GMP-compliant software, providing a comprehensive solution for clinical researchers and producers. As a result, the AppliFlex ST GMP is suited for producing materials for clinical trials and clinical manufacturing.

Regional market overview and growth insights

North America held the largest market share in the next-generation biomanufacturing market in 2024, driven by increasing prevalence of chronic disorders and rising demand for advanced biomanufacturing processes. On January 2025, Telix Pharmaceuticals Limited stated that it has completed the acquisition of antibody engineering company ImaginAb, Inc. The acquisition consists of a pipeline of next-generation treatment candidates, a proprietary innovative biologics technology platform, and a protein engineering and discovery research centre to supplement existing innovation capabilities. The technology platform and intellectual property make use of tiny, tailored antibody forms that allow for highly selective radiation-based cancer targeting while also exhibiting rapid tumor uptake and blood clearance.

Competitive Landscape and Key Competitors

The next-generation biomanufacturing market is characterized by a fragmented structure, with many competitors holding a significant share of the market. List of major players included in the next-generation biomanufacturing market report are:

• Thermo Fisher Scientific Inc
• Merck KGaA
• Hoffman La Roche
• Danaher Corporation
• Eppendorf AG
• Sartorius AG
• PBS Biotech, Inc
• ZETA GmbH
• GEA Group Aktiengesellschaft
• Applikon Biotechnology
• Esco Micro Pte Ltd
• Pierre Guerin
• Esco Group of Companies
• Shanghai Bailun Biotechnology Co. Ltd

Buy Your Exclusive Copy Now: https://navistratanalytics.com/purchase-report/757

Major strategic developments by leading competitors

Scorpius Holdings, Inc: On 04 November 2024, Scorpius Holdings, Inc., an integrated contract development and manufacturing organization, has announced a collaboration with Celltheon Corporation to offer cell line development services to clients via Celltheon's unique GOLDILOCKS transposase-based platform. This relationship allows clients to engage with Scorpius' program management team and quality system as they prepare to transfer a research cell bank (RCB) to the company's facilities in San Antonio, TX, for future biomanufacturing work.

Nature’s Toolbox, Inc.: On 04 December 2024, Nature's Toolbox, Inc. (NTx), a life science firm that develops domestically sourced biomanufacturing solutions for the delivery of tailored therapies and biologics, has secured USD 15 million in venture loans from J.P. Morgan. The funding will support the implementation of NTx systems in major pharmaceutical, government, and clinical organizations. NTx platforms will use raw materials made in the United States and contribute to the development of a complete domestic supply chain for essential biomaterials. The technique not only lowers costs and simplifies the process, but also removes toxic byproducts, making it substantially more sustainable than previous batch processes.

Unlock the Key to Transforming Your Business Strategy with Our Next-Generation Biomanufacturing Market Insights –

• Download the report summary: https://navistratanalytics.com/request-free-sample/757
• Request customization: https://navistratanalytics.com/request-customization/757

Navistrat Analytics has segmented global Next-Generation Biomanufacturing market based on Workflow Type, Application, End-Use, and region:

• Workflow Type Outlook (Revenue, USD Billion; 2022-2032)
  • Single-Use Upstream Biomanufacturing Workflow
  • Continuous Upstream Biomanufacturing
  • Downstream Biomanufacturing Workflow

• Application Outlook (Revenue, USD Billion; 2022-2032)
  • Vaccines
  • Hormones
  • Recombinant Proteins
  • Monoclonal Antibodies
  • Others

• End-Use Outlook (Revenue, USD Billion; 2022-2032)
  • Biopharmaceutical companies
  • Contract Research Organizations (CROs)
  • Academic And Research Institutions

• Regional Outlook (Revenue, USD Billion; 2022-2032)
  • North America
    1. U.S.
    2. Canada
    3. Mexico
  • Europe
    1. Germany
    2. France
    3. U.K.
    4. Italy
    5. Spain
    6. Benelux
    7. Nordic Countries
    8. Rest of Europe
  • Asia Pacific
    1. China
    2. India
    3. Japan
    4. South Korea
    5. Oceania
    6. ASEAN Countries
    7. Rest of APAC
  • Latin America
    1. Brazil
    2. Rest of LATAM
  • Middle East & Africa
    1. GCC Countries
    2. South Africa
    3. Israel
    4. Turkey
    5. Rest of MEA

Get a preview of the complete research study: https://navistratanalytics.com/report_store/next-generation-biomanufacturing-market/

About Us:

At Navistrat Analytics, we provide high-quality, comprehensive syndicated and customized market research reports that deliver actionable insights and empower businesses through data-driven strategies. Choose Navistrat Analytics as your strategic growth partner for reliable market intelligence, and let us help you navigate the complexities of the market with clarity, precision, and confidence. 

Contact Us:

Navistrat Analytics

Visit Us: www.navistratanalytics.com                        

Email Us: Sales@navistratanalytics.com      

Asia-Pacific: +91-9073010653

Follow Us LinkedIn: https://www.linkedin.com/company/navistrat-analytics/